CCN2 and diabetic kidney disease: Metformin treatment was reported to relieve the processes of inflammation and fibrosis in individuals with diabetic kidney disease by reducing the levels of the Tenascin-C, p-NF-κB (p65), connective tissue growth factor, and fibronectin proteins [83].